Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05351242

THERMotherapy Against Persistent Bacterial LUNG Infections

The aim of this study is to determine whether an intervention with frequent thermotherapy will be able to reduce the amount of colonizing bacteria in the bronchoalveolar lavage sample and eradicate the colonizing bacteria.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Herlev and Gentofte University hospital

Hellerup, Capital Region, 2900, Denmark

Location contact

josefin V Eklöf, MD

CONTACT

[email protected]

38673555 ext. +45

About this study

Normally, bacterial lung infections are acute such as community-acquired pneumonia and typically resolve after antibiotic therapy without leaving much lasting damage on the lungs. However, a great amount of persons with disrupted clearance of mucus and/or lung immune system get persistent lung infections, which can be life-long, usually do not resolve even with antibiotics, and can greatly increase morbidity and mortality. IThese persistent lung infections are thus characterized by stable periods with exacerbations inbetween, akin to chronic lung diseases such as asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. In addition, it has not been thoroughly investigated whether antibiotic regimens have an effect on disease control, as biofilm formation prevents antibiotics from killing the bacteria.

This is a randomized, controlled, multi-center, superiority trial evaluating the effect of a thermotherapy intervention, consisting of min. 7 minutes stay in min. 85℃ environment at least 4 times a week for 6 months, in persons with persistent bacterial lung infection, defined as min. 2 positive cultures during the last 24 months for one of the following bacteria: Pseudomonas aeruginosa, Achromobacter xylosoxidans, Stenotrophomonas maltophilia, Klebsiella oxytoca, Klebsiella pneumoniae, Haemophilus influenzae or Staphylococcus aureus, incl. 1 positive culture after attempted eradication therapy. The aim of the study is to investigate whether thermotherapy may offer a valid proposal for treatment of chronic lung infections.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Competent and capable
  • FEV1>1,0 L
  • Have had a positive culture from sputum or BAL min. 2 times in the last 24 months for bacteria of the species: Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Staphylococcus aureus, Haemophilus influenzae, Achromobacter xylosoxidans, Klebsiella oxytoca or Klebsiella pneumoniae. In addition, min. 1 positive culture after treatment with antibiotics
  • Willing to go to a sauna (min. temperature of 85℃ for at least 7 minutes) four times weekly for six months or avoid going to a sauna for six months

Exclusion criteria

  • Allergy to lidocaine and/or midazolam
  • Contraindications to bronchoscopy
  • Previous severe laryngospasm (intubation requiring)
  • Pregnancy/breastfeeding
  • Severe linguistic problems or inability to give informed consent
  • Severe mental illness that is not controlled with medication. NB: Patients with controlled mental illness can be included and will be asked on an equal footing as others

Treatment and study plan

Thermotherapy/sauna bath

Other

Thermotherapy/sauna bath

Primary outcomes

  1. Number of days from baseline without antibiotic treatment against pulmonary infection

    Time frame: 6 months

    This is a measure of infectious exacerbations.

Secondary outcomes

  1. Number of hospitalizations for all causes or death within 6 months

    Time frame: 6 months

  2. Changes in antibiotic usage

    Time frame: 6 months

  3. Number of antibiotic treatment regimes within 6 months

    Time frame: 6 months

  4. Eradication of the cultured bacteria at baseline, defined by a) absence of the trial inclusion bacteria or b) the participant cannot expectorate dure to dry airways.

    Time frame: 6 months

    Absence of bacteria, which lead to inclusion, is measured by a min. of 3 consecutive expectorates with a min. of 24 hours in between.

  5. Physical performance measured by distance walked over 6 minutes

    Time frame: 6 months

  6. Changes in FEV1 after 6 months

    Time frame: 6 months

  7. Clinically relevant changes in Chronic Obstructive Pulmonary Disease Assessment Test-score (range from 0-40, higher is worse) after 6 months

    Time frame: 6 months

  8. Changes in status from Medical Research Council-dyspnea score (range from 0-5, higher is worse) from <3 to 3≥, after 6 months

    Time frame: 6 months

Study contacts

Contact information is provided by the study sponsor or research team.

Jens-Ulrik S Jensen, Professor

CONTACT

[email protected]

38673057 ext. +45

Josefin V Eklöf, MD

CONTACT

[email protected]

38673555 ext. +45

Sponsors and collaborators

Lead sponsor

Chronic Obstructive Pulmonary Disease Trial Network, Denmark

Other

Registry information

Acronym: THERMA-LUNG

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Apr 28, 2022
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.